Advertisement

Advertisement
Breast Cancer

Updated Results of DESTINY-Breast03: T-DXd vs T-DM1 for Previously Treated Patients With HER2-Positive Metastatic Breast Cancer

As reported in The Lancet by Sara A. Hurvitz, MD, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival...

Pancreatic Cancer

Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer

In the phase I/II CodeBreaK 100 trial reported in The New England Journal of MedicineJohn H. Strickler, MD, and colleagues found that the KRAS G12C inhibitor...

Sarcoma
Gastrointestinal Cancer

ctDNA Analysis May Predict Optimal Treatment for Patients With GIST

Circulating tumor DNA (ctDNA) analysis ofKIT exon mutations may help predict which second-line therapy is best for patients with advanced...


Advertisement
Issues in Oncology
Survivorship

Risk of Major Psychiatric Disorders Among Survivors of Childhood and Adolescent Cancers

In a Taiwanese study reported in the Journal of Clinical Oncology, Hsu et al found that survivors of childhood and adolescent cancers were at a significantly...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Breast Cancer
Immunotherapy

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab

Prostate Cancer

Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer

Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Lymphoma

Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease

Leukemia

Ibrutinib/Venetoclax Provides Durable Remission for Patients With Newly Diagnosed CLL

The combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL). Findings from a single-institution phase II study were published by Nitin Jain, MD, and colleagues in JAMA Oncology and provide the longest ...

Kidney Cancer
Immunotherapy

No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes

A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Solid Tumors
Immunotherapy

Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care

Bladder Cancer
Immunotherapy

Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma

In a presentation of real-world data given during the 2021 ASCO Annual Meeting, Miron et al concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...